Study of the effectiveness of Probiotics and Peanut Oral Immunotherapy (P-POIT) in inducing desensitisation or tolerance in children with peanut allergy

Royal Children's Hospital0 个研究点目标入组 90 人开始时间: 2008年11月25日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•Children are eligible for the study if they:
•1) Are aged between 1 year and 10 years of age
•2) Are above 10kg
•3) There is a confirmed diagnosis of peanut allergy as defined by:
•-a positive food challenge to peanut in the past 2 years AND a positive skin prick test (SPT) or Capsulated Hydrophobic Carrier Polymer- Radioallergosorbent Test (CAP-RAST) to peanut
•-a positive food challenge or history of reaction to peanut ever AND a positive SPT greater than or equal to 8mm or a CAP-RAST greater than or equal to 15KU/l to peanut

•Children will not be eligible for the study if they have a history of:
•1) severe anaphylaxis (as defined by hypotension , collapse, loss of consciousness or hypoxia)
•2) Forced Expiratory Volume in 1 Second (FEV1) of <85% at rest or ongoing chronic persistent asthma (as per Australian Asthma Foundation guidelines)
•3) Underlying medical conditions (eg cardiac disease) that increase the risks associated with anaphylaxis
•4) Known wheat allergy (the placebo may contain traces of wheat)
•5) Use of beta-blockers
•6) Inflammatory intestinal conditions, indwelling catheters, gastrostomies or other conditions that may increase the risks of probiotic associated sepsis
•7) Cow’s milk allergy, as there may be traces of cow’s milk in the probiotic preparation
•8) Already taking probiotics

发起方